Why Experts and Indian Doctors Believe PMOS Is a More Accurate and Less Misleading Term Than PCOS

Learn why global experts and Indian doctors support this landmark change, what the latest research says, and how it may improve diagnosis, treatment, and awareness for millions of women.

For years, millions of women were told they had “cysts in the ovaries” when diagnosed with Polycystic Ovary Syndrome (PCOS). Yet many of them never actually had ovarian cysts. Others had symptoms far beyond the ovaries, including insulin resistance, weight gain, acne, infertility, anxiety, cardiovascular risk, and metabolic dysfunction.

Now, after more than a decade of international research and consultation, the medical community has officially introduced a new name: Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change was announced in 2026 through a landmark global consensus published in The Lancet and supported by more than 50 international academic, clinical, and patient organizations.  

This is not just a cosmetic name change. Experts say it reflects a major shift in how the condition is understood, diagnosed, and treated.

Why the Term “PCOS” Was Considered Misleading

The older name, Polycystic Ovary Syndrome, created confusion from the beginning. The term suggested three things:

• The condition is mainly about ovaries

• Ovarian cysts are necessary for diagnosis

• It is primarily a gynecological disorder

However, modern evidence has shown that none of these assumptions are entirely accurate.

Many women diagnosed with PCOS do not have ovarian cysts on ultrasound. What are commonly seen are immature follicles, not true cysts. At the same time, many women with polycystic-appearing ovaries may not have the syndrome at all.  

Indian doctors and endocrinologists have increasingly argued that the old terminology caused delayed diagnosis and fragmented care. Patients with symptoms like insulin resistance, obesity, hair thinning, fatigue, acne, mood disorders, or irregular ovulation were often treated symptom-by-symptom instead of receiving holistic care.

Experts now believe the name itself unintentionally narrowed the clinical approach.

What Does PMOS Mean?

The new name — Polyendocrine Metabolic Ovarian Syndrome — was chosen carefully to reflect the multisystem nature of the disorder.

“Polyendocrine”

This highlights that multiple hormonal systems are involved, not just the ovaries. Hormones related to insulin, androgens, adrenal function, and reproductive regulation are all interconnected.

“Metabolic”

This is perhaps the most important addition. Research now strongly links the condition to:

• Insulin resistance

• Prediabetes and type 2 diabetes

• Weight dysregulation

• Cardiovascular risk

• Fatty liver disease

• Chronic inflammation

By including “metabolic” in the name, doctors hope women and clinicians will take these long-term health risks more seriously.  

“Ovarian Syndrome”

The ovaries are still involved, especially in ovulation and fertility issues, but they are no longer portrayed as the sole focus of the disease.

The Landmark Global Consensus Behind the Change

The renaming process was not sudden. It followed a 14-year international collaboration involving:

• Researchers

• Endocrinologists

• Gynecologists

• Mental health experts

• Patient advocacy groups

• Women living with the condition

According to the  Endocrine Society, over 22,000 stakeholders contributed to surveys, workshops, and consensus-building exercises before the final terminology was adopted.  

The final consensus was published in The Lancet and presented at the European Congress of Endocrinology in 2026.  

Professor Helena Teede, one of the leading experts behind the initiative, stated that the older name reduced a complex endocrine condition into a misunderstood “ovarian cyst problem,” contributing to underdiagnosis and inadequate treatment.  

Why Indian Doctors Strongly Support the Change

India has one of the highest burdens of PCOS globally, particularly among urban adolescents and young women. Some Indian studies estimate that nearly 1 in 5 young women may be affected.  

Indian clinicians have increasingly observed that patients often:

• Ignore symptoms if they do not have “cysts”

• Believe it is only a fertility issue

• Seek treatment only for cosmetic concerns like acne or facial hair

• Remain unaware of future diabetes or cardiovascular risks

According to experts quoted in AIIMS discussions and Indian medical coverage, the term PMOS may improve early screening because it better communicates the condition’s metabolic and endocrine nature.  

Indian doctors also believe the new terminology may reduce stigma. Many patients associated the word “cyst” with severe disease, tumors, or infertility, causing unnecessary fear and shame.

By reframing the condition as a broader hormonal-metabolic syndrome, the conversation becomes more scientifically accurate and less emotionally distressing.

The Role of the 2023 International Evidence-Based Guideline

The renaming movement was deeply influenced by the 2023 International Evidence-Based Guideline for PCOS assessment and management, led largely by Australian researchers and global collaborators.  

The guideline emphasized that the condition affects:

• Reproductive health

• Metabolic health

• Cardiovascular risk

• Mental wellbeing

• Dermatological health

It also highlighted the need for multidisciplinary care involving:

• Gynecologists

• Endocrinologists

• Dietitians

• Mental health professionals

• Fertility specialists

This evidence-based approach reinforced the argument that the old name no longer reflected scientific understanding.

How the New Name Could Improve Diagnosis

One of the biggest goals of the PMOS terminology is earlier and more accurate diagnosis.

Under the older framework, women without visible ovarian cysts were sometimes dismissed despite having:

• Irregular periods

• Elevated androgen levels

• Insulin resistance

• Hair loss

• Acne

• Weight issues

Experts say the PMOS framework encourages clinicians to look at the entire endocrine-metabolic picture instead of focusing mainly on ultrasound findings.  

This is especially important for:

• Lean PMOS patients

• Adolescents

• Women with regular-looking cycles but poor ovulation

• Patients with metabolic dysfunction but subtle gynecological symptoms

Mental Health and the PMOS Shift

Another major reason behind the renaming is mental health awareness.

Research increasingly shows that women with the condition face higher rates of:

• Anxiety

• Depression

• Body image issues

• Eating disorders

• Social stigma

Many patients reported feeling unheard because the term PCOS minimized their broader symptoms. Online communities and patient groups frequently discussed how the “ovary-focused” terminology failed to explain fatigue, mood changes, and metabolic struggles.  

The PMOS terminology validates the fact that this is a whole-body disorder rather than simply a reproductive issue.

Will the Diagnosis Criteria Change?

At present, the diagnostic criteria remain largely based on the Rotterdam criteria:

• Irregular ovulation

• Elevated androgens

• Polycystic ovarian morphology

Two out of three are still typically required for diagnosis.  

However, experts believe the broader PMOS framework may eventually encourage more comprehensive metabolic screening, including:

• Insulin resistance testing

• Lipid profiles

• Mental health assessment

• Cardiovascular risk evaluation

A Shift That Reflects Modern Medicine

The move from PCOS to PMOS represents more than updated terminology. It reflects a deeper evolution in women’s healthcare.

For decades, many women struggled with delayed diagnosis because medicine focused too narrowly on the ovaries. The newer understanding recognizes that the condition involves hormones, metabolism, inflammation, mental health, and long-term systemic risk.

By adopting the term PMOS, experts hope to:

• Improve public awareness

• Encourage earlier diagnosis

• Reduce stigma

• Promote multidisciplinary care

• Improve long-term health outcomes

For millions of women worldwide, including a rapidly growing population in India, the name change may finally align medical language with medical reality.